HUTCHMED

London: Wednesday, 24 April 2013: Nutrition Science Partners, a 50/50 joint venture between Chi-Med and Nestlé Health Science, today announces that the first patient has been enrolled and has begun treatment in the first global Phase III study of HM

2013 Annual Report and Notice of Annual General Meeting

Final Results for the year ended 31 December 2013

TR-1: Notification of major interest in shares

Notice of Announcement of 2013 Final Results

Blocklisting Six Monthly Return

Chi-Med and Sinopharm form China drug distribution and marketing joint venture

Director's Shareholding

Chi-Med's Pharmaceutical R&D Business - Analyst & Investor Briefing

Candidate Nomination of Novel Small-Molecule Therapy in Inflammation Triggers Milestone Payment From Janssen Pharmaceuticals, Inc.

Cancer Therapy Collaboration with Lilly

Analyst briefing on Chi-Med's pharmaceutical R&D business on 9 October 2013

TR-1: Notification of major interest in shares

Director's Shareholding

Interim Results for the Six Months Ended 30 June 2013

Nutrition Science Partners announces initiation of NATRUL-4, the maintenance study of the global Phase III trial for HMPL-004

Blocklisting Six Monthly Return

Initiation of Volitinib China Phase I study triggers US$5 million milestone payment

Notice of Announcement of 2013 Interim Results

Results of Annual General Meeting

Nutrition Science Partners announces initiation and treatment of the first Ulcerative Colitis patient in the global NATRUL Phase III trial for the novel botanical oral drug HMPL-004

Nestlé Health Science and Chi-Med complete regulatory approvals for the establishment of Nutrition Science Partners Joint Venture

2012 Annual Report and Notice of Annual General Meeting

Presentations of Fruquintinib Phase I Clinical Data and Volitinib Preclinical Data at the 2013 AACR Annual Meeting

Final Results for the year ended 31 December 2012

Total Voting Rights

Notice of Announcement of 2012 Final Results

TR-1: Notification of major interest in shares

Blocklisting Six Monthly Return

Chi-Med and Nestlé Health Science establish Joint Venture

Hutchison MediPharma Limited initiates Phase I clinical study with its novel EGFR inhibitor Theliatinib

TR-1: Notification of major interest in shares

Total Voting Rights

Director's Shareholding

Change of Nominated Adviser

Interim Results for the Six Months Ended 30 June 2012

Total Voting Rights

Announcement on Blocklisting Six Monthly Return

Notice of Announcement of 2012 Interim Results

Exercise of Options

Hutchison MediPharma Limited Announces Presentations of Sulfatinib and Fruquintinib Clinical Data at the 2012 ASCO Annual Meeting

Director's Shareholding

Results of Annual General Meeting

2011 Annual Report and Notice of Annual General Meeting

Final Results for the year ended 31 December 2011. Strong growth. Positive outlook

Hutchison MediPharma Limited initiates Phase I clinical study of its novel c-Met inhibitor Volitinib

Notice of Announcement of 2011 Final Results

TR-1: Notification of major interests in shares

Total Voting Rights

TR-1: Notification of major interest in shares

Blocklisting Six Monthly Return